Featured Research

from universities, journals, and other organizations

High Levels Of Antibodies, Low Levels Of Cancer?

Date:
April 17, 2007
Source:
Austrian Science Fund
Summary:
Active immunisation can stimulate the body to produce highly efficient IgE antibodies that attack tumours. This breakthrough, achieved in an animal model, is based on the skillful combination of two established experimental methods.

Cancer vaccine: Antibodies known from allergic reactions can also be targeted against tumours.
Credit: Erika Jensen-Jarolim

Active immunisation can stimulate the body to produce highly efficient IgE antibodies that attack tumours. This breakthrough, achieved in an animal model, is based on the skillful combination of two established experimental methods. The results are now being published in Cancer Research and are part of a project funded by the Austrian Science Fund FWF. The antibodies produced during the project belong to a class that also plays a key role in the development of allergic reactions.

Related Articles


People who suffer from allergies are well acquainted with immunoglobulin E (IgE). It is this class of antibodies that plays a key role in causing an allergy sufferer's immune system to overreact. Oncologists too are very familiar with IgE. Numerous in-depth studies have shown that those with raised levels of IgE are much less likely to suffer from certain types of cancer. Or in other words - allergy sufferers are at a lower risk of developing cancer.

Allergy & Cancer

"In actual fact, the IgE produced during an allergic reaction does not attack cancer tumours but instead attacks allergens, for example pollen," explains the study's leader, Prof. Erika Jensen-Jarolim, head of the Department of Pathophysiology at the Medical University of Vienna. "The fact that IgE nevertheless acts against tumours is more of a fortunate side-effect of the highly efficient characteristic of this antibody class. It was our aim to make this antibody class, which is typical for allergies, act directly against tumours. At the same time, we wanted to encourage the long-term production of IgE in the body by means of active immunisation."

Prof. Jensen-Jarolim's group recently succeeded in achieving the latter - active immunisation against certain types of tumour - in mice. However, due to the selected type of immunisation (injection below the abdominal wall) the antibodies that were produced belonged to the IgG class. This type of antibody produces a much more limited and shorter-term effect against tumours than IgE antibodies.

Through the Stomach

Prof. Jensen-Jarolim used one of her group's earlier successes - achieved as part of another FWF project on food allergies - to ensure that immunisation resulted in the intended activation of IgE. These findings prove that food proteins are effective in inducing IgE-dependent immune reactions when they withstand the acidic environment of the stomach.

Prof. Jensen-Jarolim's team therefore fed mice a peptide very similar to a tumour peptide while reducing acidification in the stomach, thereby hindering digestion of the peptide. As a result, a type of allergic reaction was triggered against this tumour-like peptide - the mice produced tumour-specific IgE antibodies. The result is the world's first active IgE-stimulating tumour vaccination.

Reference: Active Induction of Tumor-Specific IgE Antibodies by Oral Mimotope Vaccination. Angelika B. Riemer, Eva Untersmayr, Regina Knittelfelder, Albert Duschl, Hubert Pehamberger, Christoph C. Zielinski, Otto Scheiner and Erika Jensen-Jarolim. Cancer Research, doi: 10.1158/0008-5472.CAN-06-3758


Story Source:

The above story is based on materials provided by Austrian Science Fund. Note: Materials may be edited for content and length.


Cite This Page:

Austrian Science Fund. "High Levels Of Antibodies, Low Levels Of Cancer?." ScienceDaily. ScienceDaily, 17 April 2007. <www.sciencedaily.com/releases/2007/04/070416170327.htm>.
Austrian Science Fund. (2007, April 17). High Levels Of Antibodies, Low Levels Of Cancer?. ScienceDaily. Retrieved October 31, 2014 from www.sciencedaily.com/releases/2007/04/070416170327.htm
Austrian Science Fund. "High Levels Of Antibodies, Low Levels Of Cancer?." ScienceDaily. www.sciencedaily.com/releases/2007/04/070416170327.htm (accessed October 31, 2014).

Share This



More Health & Medicine News

Friday, October 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Melafind: Spotting Melanoma Without a Biopsy

Melafind: Spotting Melanoma Without a Biopsy

Ivanhoe (Oct. 31, 2014) The MelaFind device is a pain-free way to check suspicious moles for melanoma, without the need for a biopsy. Video provided by Ivanhoe
Powered by NewsLook.com
Battling Multiple Myeloma

Battling Multiple Myeloma

Ivanhoe (Oct. 31, 2014) The answer isn’t always found in new drugs – repurposing an ‘old’ drug that could mean better multiple myeloma treatment, and hope. Video provided by Ivanhoe
Powered by NewsLook.com
Chronic Inflammation and Prostate Cancer

Chronic Inflammation and Prostate Cancer

Ivanhoe (Oct. 31, 2014) New information that is linking chronic inflammation in the prostate and prostate cancer, which may help doctors and patients prevent cancer in the future. Video provided by Ivanhoe
Powered by NewsLook.com
Sickle Cell: Stopping Kids’ Silent Strokes

Sickle Cell: Stopping Kids’ Silent Strokes

Ivanhoe (Oct. 31, 2014) Blood transfusions are proving crucial to young sickle cell patients by helping prevent strokes, even when there is no outward sign of brain injury. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins